{"id":1012238,"date":"2026-10-21T16:22:02","date_gmt":"2026-10-21T20:22:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/"},"modified":"2026-10-21T16:22:02","modified_gmt":"2026-10-21T20:22:02","slug":"revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/","title":{"rendered":"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">REDWOOD CITY, Calif., Oct.  21, 2026  (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.<\/p>\n<p align=\"left\">To listen to the live webcast, or access the archived webcast, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9f3UUGb08W_6tJS-pCEN73Fz15cc-wKY6adlrXYjjjzNDVK-Y3o0aVvx_RNozk9dkrPYaBvx8qJaYLdUbIzgfJWWMKm2wSf3CCLQvmtn-j0US_hpeBFuz7sOhhtFm5IjDlYhQ6DaSpiCYO4ZsBg2kKCTemyX0KppY2tOiYlnyOOy4wjcfSUfI0Pgkd7yWJZXHn36yIyrr0pOCr7muRi7sXjaf8lW8PUlxi-YkNltHpjt0XaFOiaAWWbpsT29ZBf6sJouDQhG-1jNnTss5PiVCXgNAyWb0vbfw6t_diXQ782KMGEn7J8Tpnv0RLge48vHW_XxhAQ9HoOvXkVPzwZMrjfUsb0cIK19oiUNIOOh1ol-NtjEbwqcjTq2Ps-iClSn\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.revmed.com\/events-and-presentations<\/a>. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days.<\/p>\n<p align=\"left\">\n        <strong>About Revolution Medicines, Inc.<\/strong><br \/>\n        <br \/>Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ybjz5GKdCaFlAAlIOSXWmibhmUa47DNAFC3VtEyHts_9iCbMpkEj24KApRb8zJZAikQ1l1ogOMWdNjIZI3C6BZNLYy_aBxFl2l48C7HZI2ZE14EOW3QVIVvApnSxFzsBSY4L9WkjatIJbEfcNcQEnWWdilOPr3Z5LyQUoXQCy5NRPA4OiKnrULcu8WI-plVi7gJUcrQVgRMs2V4HaEiqwS8L5p1MxVAfN3aISLUtxljCMHgN91nJWYSF-TXKZiHdLVfx6RJ1cbpRYiYqkv43krIgiew3guJEBr-7jN4wDzXN_zzHCp39j3-5f2-NVtoaqUEUqOlXN3bWWu1NdqmfNNza-jswDJd7jFtlU8SQcFknt2QZnNWxNfjiqSHvfgmNh7aHnawj4KUL-y4_sKWkvDNZnL5S4CycqCrbWC-p_Lk=\" rel=\"nofollow\" target=\"_blank\">www.revmed.com<\/a> and follow Revolution Medicines on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xT80E3bLZDNc8IppLtOCo6qPdTb6txtvBN-jfAsR74JyICI0tuGD8vm1qIVJMx2CLNStwEGKcN1IeHVfQl8e0PV1HgDtAxJrh-GaJkZ-VAYa5QZbpU-S7XMmw7PHFnqNKRk5A-Apb4Rzom0snxaYviSk4isRM38KaGCIxaKlq1jqR4jHrqOgiuHKrVI8fDrgOAk07fp3wCvCSCOJYhVOXeYexZrgMD9z8jXTQzW0dZc3wthvpdE47oxl8MYNH6oyC6rzDfEqjZUhwQQBNjv_abBOQOijEWNAu_IKcJilHJa0djirWqLA8nFQOdL5zdysisv4ypD5watGDAol9ibJN8G3yA95uycYCuK_R8AnCrElH15oyXMy8HybReUtgV7GiexCzRrw8s44GUOffdXZtxNZB3flQAoxpKDyDnhkriJCn1YxDGE2o7rZ4UkkKleUNKdDPEkSsKoH-ylXAFAFkqK_-PqjmmgeeRffzFcsJH0=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RKbsyNt7fF69XkPPGzyMEyDh7HZV1YACf5ElfNBiFzOp4rYgr6zNylM8GHiwdetAVImpct1RO2LOftElHqOhJMgaYNJYCHFSxwRONj_dltESTxzWHakF_71SUuvZ9LK2v9WpgGeKtDKCiK3uCp0ArDnQNgt1NJo10kQKBpAUAq_6RZ_WoOkTEI6NFH3VBzH6VvFC2yYn_mTnO9gzMWFkP4ovMR_IpsUsNbAva_nH6cBo1ukne_i1MYI3NsHyJyYj_Akd4UE0i69GLW8aBUuNJnhXwolfeO636JHuynIvjigZE0YtBGgHE0I7CuRjFNmPgFo4tovVjw-D0fRv49qYaJKhERgvEYhimCRbjeItgM5T3wp9n89v2Eiz7AmZIYUs\" rel=\"nofollow\" target=\"_blank\">X<\/a> (Twitter) and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5O47gI4VgRJxUMr_uyXKkSwiI-FLqZQ_rpkJLxebqP2uj9Jexho4cA8MxHwmddM1VXV4hFmssNoUe7M8xTGSB_c8-p-83k0lk0mxOBuXkpccTdVRS_G0wwdXbod6h4fO7WfSpf4KxfBmIfD3fuCFQm6k1jll6A5NO6H5AEMz4EIpCykDYiJG3IrkDa2_iNeNnxNf8oiGmSGA24dSQnx-YtVG6hGNJQJWrqrQg8xG8Fh9-4O8DZhRMcyWNt1UzyR1nrGfpYNDeoYfl0Gcwxxsryt_EnqVV5ULN3y8KbMHbQ2M4uFddy7dMfOoDIIgkrrt2aIHNh9_6Bzn5gbuJTfbBi0UxhGQbFTSBgzCqr-p8y0bMXEgvrqHZbv3bNZdW2dhBBU9fdYnNra9yuQpGJiDudi76h73oiTZW_naJUVJp1r1y1hu5jnj53LO9vzNCGbSzfONp0sQCiZDcpd5XyNAhIqwhm_rNFFgFVyVDB_m0Ak=\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Revolution Medicines Media &amp; Investor Contact:<\/strong><br \/>\n        <br \/>media@revmed.com<br \/>investors@revmed.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGMzZDhmYzItOTg4My00ODljLWJlMTctZTljYmY4OTc4ZmY5LTEyMDU1ODctMjAyNi0xMC0yMS1lbg==\/tiny\/Revolution-Medicines-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012238","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days. &hellip; Continue reading &quot;Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-21T20:22:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026\",\"datePublished\":\"2026-10-21T20:22:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/\"},\"wordCount\":246,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/\",\"name\":\"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=\",\"datePublished\":\"2026-10-21T20:22:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/","og_locale":"en_US","og_type":"article","og_title":"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days. &hellip; Continue reading \"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-21T20:22:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026","datePublished":"2026-10-21T20:22:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/"},"wordCount":246,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/","name":"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=","datePublished":"2026-10-21T20:22:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDQ4OSM3OTA2MzUxIzIxOTQwMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012238"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012238\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}